Healthcare

How Chinese Biopharma Innovation is Forging the Future of Global Oncology Deal Making.

Regulators, payers and clinicians are asking for more than traditional real world evidence (RWE). They want to understand how treatments affect people’s daily lives - not just what is written in the case report form. But how can you build patient-centric evidence that stands up to scientific, regulatory and commercial scrutiny?

Ipsos' leading cardiometabolic experts took the stage with to unpack one of the most dynamic therapeutic areas in healthcare today.

2025, 2026, Predictions … Ipsos Update explores the latest research and thinking on key topics from Ipsos teams around the world.

The cancer treatment landscape continues to evolve at speed. For all those working in oncology today, being able to adeptly respond to these shifts is imperative for brand success.

Powered by expert analysis and data-driven insights, our annual Year in Review report looks back at the key events, shifts and challenges of 2025 and reflects on what this tells us about the year to come.

Turn longevity from trend to strategy: where should pharma play - and how to win?

Despite media discussions around the drugs, only around a third across 30 countries have heard about the drugs, with a lot of the discourse taking place via social media according to the Ipsos Health Service Report.

Healthcare, Indulgence, Risk … Ipsos Update explores the latest research and thinking on key topics from Ipsos teams around the world.